Last reviewed · How we verify
Low dose erythropoietin
Low-dose erythropoietin stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production.
Low-dose erythropoietin stimulates erythroid progenitor cells in the bone marrow to increase red blood cell production. Used for Anemia of chronic kidney disease, Anemia associated with chronic disease.
At a glance
| Generic name | Low dose erythropoietin |
|---|---|
| Also known as | Low dose |
| Sponsor | VA Office of Research and Development |
| Drug class | Erythropoiesis-stimulating agent |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Erythropoietin (EPO) is a cytokine that binds to the erythropoietin receptor on hematopoietic stem cells, promoting their differentiation and proliferation into mature red blood cells. At low doses, it is used to treat anemia by boosting endogenous erythropoiesis without the thromboembolic risks associated with higher doses used in cancer-related anemia.
Approved indications
- Anemia of chronic kidney disease
- Anemia associated with chronic disease
- Chemotherapy-induced anemia
Common side effects
- Hypertension
- Thromboembolism (venous thromboembolism, stroke)
- Headache
- Flu-like symptoms
- Injection site reactions
Key clinical trials
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
- A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (PHASE3)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India (PHASE4)
- Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients (EARLY_PHASE1)
- Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage (PHASE1)
- Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies (PHASE2)
- Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose erythropoietin CI brief — competitive landscape report
- Low dose erythropoietin updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI